PALO ALTO, Calif., June 15 /PRNewswire/ -- Anacor Pharmaceuticals, a privately-held pharmaceutical company developing novel agents for inflammatory and infectious diseases, today announced promising data from a Phase 2a study of AN0128, a novel topical anti-inflammatory drug candidate for atopic dermatitis (AD), a disease affecting approximately 15 million Americans.
